LGND (STOCKS)
Ligand Pharmaceuticals Inc.
$219.000000
+14.080000 (+6.87%)
Prev close: $204.920000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Todd Christopher Davis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,256.24M
- Employees
- 68
- P/E (TTM)
- 33.42
- P/B (TTM)
- 3.98
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$2.02 | $1.59 | +0.4274 | +26.84% |
|
Sep 2025 (Q3)
|
$3.09 | $1.96 | +1.1258 | +57.32% |
|
Jun 2025 (Q2)
|
$1.60 | $1.45 | +0.1501 | +10.35% |
|
Mar 2025 (Q1)
|
$1.33 | $1.24 | +0.0941 | +7.61% |
Financial Statements
| Revenues | $268.09M |
| Benefits Costs and Expenses | $109.13M |
| Costs And Expenses | $109.13M |
| Nonoperating Income/Loss | $117.96M |
| Operating Expenses | $227.09M |
| Research and Development | $81.18M |
| Other Operating Expenses | $145.90M |
| Operating Income/Loss | $41.00M |
| Income/Loss From Continuing Operations After Tax | $124.45M |
| Income/Loss From Continuing Operations Before Tax | $158.96M |
| Income/Loss From Equity Method Investments | $0.00 |
| Income Tax Expense/Benefit | $34.51M |
| Income Tax Expense/Benefit, Current | $12.62M |
| Income Tax Expense/Benefit, Deferred | $21.89M |
| Net Income/Loss | $124.45M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $124.45M |
| Net Income/Loss Available To Common Stockholders, Basic | $124.45M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $6.44 |
| Diluted Earnings Per Share | $6.13 |
| Basic Average Shares | 19,338,000 |
| Diluted Average Shares | 20,294,000 |
| Assets | $1.56B |
| Current Assets | $832.27M |
| Inventory | $9.13M |
| Other Current Assets | $823.15M |
| Noncurrent Assets | $728.37M |
| Fixed Assets | $3.57M |
| Intangible Assets | $225.44M |
| Other Non-current Assets | $499.36M |
| Liabilities | $543.43M |
| Current Liabilities | $37.45M |
| Accounts Payable | $3.24M |
| Interest Payable | $1.31M |
| Wages | $6.39M |
| Other Current Liabilities | $26.51M |
| Noncurrent Liabilities | $505.98M |
| Equity | $1.02B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.02B |
| Liabilities And Equity | $1.56B |
| Net Cash Flow From Operating Activities | $49.36M |
| Net Cash Flow From Operating Activities, Continuing | $49.36M |
| Net Cash Flow From Investing Activities | -$377.32M |
| Net Cash Flow From Investing Activities, Continuing | -$377.32M |
| Net Cash Flow From Financing Activities | $428.22M |
| Net Cash Flow From Financing Activities, Continuing | $428.22M |
| Exchange Gains/Losses | $2.36M |
| Net Cash Flow | $102.62M |
| Net Cash Flow, Continuing | $100.26M |
| Comprehensive Income/Loss | $138.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $138.85M |
| Other Comprehensive Income/Loss | $138.85M |